Prevention of immune responses to human erythropoietin in cynomolgus monkeys (Macaca fascicularis).

Genes and proteins of human origin are often administered to monkeys for research purposes, however, it can be difficult to obtain sufficient levels of the products in vivo due to immunological clearance. In this study, we showed that human erythropoietin (hEPO) induces generation of anti-hEPO antibody in cynomolgus macaques (n=2), although 92% of amino acid residues are common between the human and macaque EPO. The administered hEPO was thus eliminated from the animals. On the other hand, when an immunosuppressant, cyclosporin A (CyA), was administered (6 mg/kg) intramuscularly every other day in combination with hEPO (n=2), no anti-hEPO antibody was generated and high serum levels of hEPO were obtained during administration of hEPO, resulting in an increase in serum hemoglobin levels. No adverse effects associated with CyA were observed. Thus, CyA treatment is useful for prevention of immune responses associated with the administration of human proteins in monkeys.

[1]  E. Gromnica-ihle,et al.  Development and evaluation of a new ELISA for the detection and quantification of antierythropoietin antibodies in human sera. , 2004, Journal of immunological methods.

[2]  M. Taniwaki,et al.  High-level in vivo gene marking after gene-modified autologous hematopoietic stem cell transplantation without marrow conditioning in nonhuman primates. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  M. Nagao,et al.  Improvement of anemia associated with chronic renal failure by recombinant human erythropoietin treatment in ICR-derived glomerulonephritis (ICGN) mice. , 2004, The Journal of veterinary medical science.

[4]  C. Rübe,et al.  Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial , 2003, The Lancet.

[5]  K. Ozawa,et al.  In vivo selective expansion of gene-modified hematopoietic cells in a nonhuman primate model , 2002, Gene Therapy.

[6]  S. Karlsson,et al.  Long-term in vivo expression of the human glucocerebrosidase gene in nonhuman primates after CD34+ hematopoietic cell transduction with cell-free retroviral vector preparations. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[7]  J. Pirsch,et al.  Long-term efficacy and safety of cyclosporine in renal-transplant recipients. , 1994, The New England journal of medicine.

[8]  William Arbuthnot Sir Lane,et al.  Isolation of the cyclosporin-sensitive T cell transcription factor NFATp. , 1993, Science.

[9]  A. Nademanee,et al.  Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. , 1993, The New England journal of medicine.

[10]  T. Curran,et al.  The T-cell transcription factor NFATp is a substrate for calcineurin and interacts with Fos and Jun , 1993, Nature.

[11]  H. Ohto,et al.  Recombinant human erythropoietin for autologous blood donation: effects on perioperative red-blood-cell and serum erythropoietin production , 1992, The Lancet.

[12]  C. H. Lin,et al.  Monkey erythropoietin gene: cloning, expression and comparison with the human erythropoietin gene. , 1986, Gene.